Photodynamic Therapy in Dentistry: Antimicrobial and Oncological Applications
Photodynamic therapy (PDT) is a minimally invasive therapeutic modality that combines a photosensitizing agent, light of a specific wavelength, and molecular oxygen to produce cytotoxic reactive oxygen species. Originally developed for oncological applications, PDT has been increasingly adopted in dentistry for its dual antimicrobial and antineoplastic properties. This article examines the mechanisms, clinical applications, evidence base, and future directions of photodynamic therapy in dental practice.
Mechanisms of Action
PDT operates through a photochemical reaction requiring three components: a photosensitizer, light, and oxygen. The photosensitizer is a light-sensitive compound that preferentially accumulates in target cells or microorganisms. When activated by light of a specific wavelength corresponding to its absorption peak, the photosensitizer transitions from a ground singlet state to an excited triplet state. In the presence of molecular oxygen, this excited photosensitizer transfers energy through two competing pathways: Type I reactions generate superoxide anions, hydrogen peroxide, and hydroxyl radicals; Type II reactions generate singlet oxygen, the most cytotoxic species. These reactive oxygen species (ROS) cause oxidative damage to cellular membranes, proteins, lipids, and nucleic acids, leading to target cell death through necrosis or apoptosis.
Antimicrobial PDT (aPDT) exploits the differential accumulation of photosensitizers in microbial cells versus host tissues. The cationic charge of commonly used photosensitizers such as methylene blue, toluidine blue O, and indocyanine green facilitates binding to the negatively charged surface of bacterial cells. aPDT is effective against Gram-positive and Gram-negative bacteria, fungi, viruses, and protozoa, and importantly, does not induce antimicrobial resistance — a critical advantage in an era of increasing antibiotic resistance. The multi-target oxidative mechanism makes it virtually impossible for microorganisms to develop resistance through single-gene mutations.
Photosensitizers and Light Sources
Photosensitizers used in dentistry include phenothiazinium dyes (methylene blue, toluidine blue O), porphyrins and their derivatives (photofrin, hematoporphyrin), chlorins, phthalocyanines, and naturally derived compounds such as curcumin and riboflavin. The ideal photosensitizer should exhibit high selectivity for target cells, low dark toxicity, rapid clearance from healthy tissues, strong absorption in the therapeutic window (600 to 800 nm for deeper tissue penetration), and high singlet oxygen quantum yield. Second-generation photosensitizers, including 5-aminolevulinic acid (5-ALA), are prodrugs that are metabolized intracellularly to the active photosensitizer protoporphyrin IX, providing enhanced selectivity.
Light sources have evolved from early argon-pumped dye lasers to more compact and affordable light-emitting diode (LED) systems and diode lasers. LED devices offer narrow-band emission matched to specific photosensitizer absorption peaks, portability, and lower cost, making them suitable for routine clinical use. Diode lasers (635 to 810 nm) are also commonly employed and can be used for both PDT and conventional laser applications.
Periodontal Applications
The most extensively studied dental application of aPDT is as an adjunct to scaling and root planing (SRP) in the treatment of chronic and aggressive periodontitis. Periodontitis is a biofilm-mediated inflammatory disease; mechanical debridement alone may incompletely eliminate subgingival pathogens, particularly in deep pockets, furcation involvements, and areas of difficult access. aPDT is applied by introducing the photosensitizer solution into the periodontal pocket, allowing incubation for 1 to 3 minutes, followed by light irradiation via a fiber optic tip.
Systematic reviews and meta-analyses demonstrate that aPDT as an adjunct to SRP provides statistically significant improvements in clinical attachment level (CAL) gain (weighted mean difference of 0.3 to 0.5 mm) and probing depth (PD) reduction (weighted mean difference of 0.3 to 0.6 mm) at 3 to 6 months compared to SRP alone, particularly in deep pockets and in patients with aggressive periodontitis. Microbiological outcomes show significant reductions in Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, and Aggregatibacter actinomycetemcomitans. The benefits are most pronounced in sites with initially deeper probing depths and in patients with compromised healing capacity, such as smokers and immunocompromised individuals.
Peri-Implant Disease
Peri-implant mucositis and peri-implantitis are inflammatory conditions affecting the tissues surrounding dental implants, driven by biofilm accumulation on implant surfaces. The complex surface topography of implants complicates mechanical debridement. aPDT has emerged as an adjunctive treatment for both peri-implant mucositis and peri-implantitis, demonstrating reductions in bleeding on probing, probing depth, and microbial load. In peri-implantitis, aPDT may be combined with surgical access and implant surface decontamination. Limited evidence suggests that aPDT may provide an advantage over mechanical debridement alone in non-surgical treatment of peri-implant mucositis, though its role in surgical peri-implantitis therapy remains investigational.
Endodontic Applications
Root canal disinfection is a critical determinant of endodontic treatment success. Despite advances in instrumentation and irrigation, complete bacterial eradication from the complex root canal system remains challenging, with reported failure rates of 10% to 15%. aPDT has been investigated as an adjunctive disinfection protocol following chemomechanical preparation. The photosensitizer is introduced into the root canal system, and a fiber optic tip delivers light throughout the canal length. In vitro studies demonstrate significant reductions in Enterococcus faecalis, Candida albicans, and multispecies biofilms. Clinical studies show improved microbial reduction compared to conventional irrigation alone, though the evidence for enhanced healing outcomes is limited, and aPDT is currently considered an adjunct rather than a replacement for conventional irrigation protocols.
Oncological Applications in the Oral Cavity
PDT utilizing 5-ALA or Photofrin has been employed for the treatment of oral potentially malignant disorders (OPMDs), including oral leukoplakia, erythroplakia, and oral lichen planus with dysplastic features. PDT offers the advantage of selective destruction of dysplastic and malignant cells while sparing surrounding normal tissues, minimal scarring, and the ability to treat field cancerization. Complete response rates for oral leukoplakia range from 60% to 90%, with recurrence rates of 10% to 30% at one year.
For early-stage oral squamous cell carcinoma (Tis, T1, T2), PDT can be an alternative to surgery or radiotherapy in selected patients, particularly for lesions in anatomically challenging locations or in patients with significant comorbidities. PDT preserves organ function, avoids the cumulative toxicity of radiation, and can be repeated without loss of efficacy. A limitation is the depth of light penetration, restricting treatment to superficial lesions (less than 5 to 10 mm). For advanced tumors, PDT is primarily palliative, providing local tumor control, debulking, and symptom relief.
Cariology and Restorative Dentistry
aPDT has been explored as a method for caries disinfection, targeting cariogenic bacteria including Streptococcus mutans and Lactobacillus species. In deep caries management, aPDT may be applied prior to pulp capping or restoration placement to reduce the bacterial load without the need for complete infected dentin removal, supporting minimally invasive caries excavation techniques. Evidence remains preliminary, with most data derived from in vitro and small clinical studies.
Safety and Limitations
PDT is generally well tolerated with minimal side effects. Patients must be counseled about photosensitivity, as residual photosensitizer in the skin can cause phototoxic reactions upon exposure to sunlight or bright indoor light, requiring avoidance of direct sunlight for 24 to 48 hours post-treatment with systemic photosensitizers. Local photosensitizers applied topically pose negligible systemic photosensitivity risk. Pain during light application is transient and manageable. The primary limitation of PDT is the limited tissue penetration depth of light (typically 5 to 10 mm for wavelengths in the therapeutic window), restricting treatment to superficial lesions. The cost of equipment and lack of standardized protocols are barriers to widespread clinical adoption.
Conclusion
Photodynamic therapy represents a promising, minimally invasive therapeutic adjunct in multiple domains of dentistry. Its dual antimicrobial and antineoplastic capabilities, combined with a favorable safety profile and the absence of induced antimicrobial resistance, position it as a valuable tool in contemporary dental practice. The strongest clinical evidence supports its use as an adjunct to SRP in periodontal therapy and as a treatment modality for oral potentially malignant disorders. Future research should focus on developing tissue-specific photosensitizers, optimizing light delivery systems, and establishing standardized clinical protocols to facilitate broader implementation.
